Misteltherapie bij kanker

Verbetering van Overleving (Survival)

1. Geavanceerde Pancreaskanker:
   • Trial: Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer.
   • Resultaat: Median overleving was 4.8 maanden voor de VaL groep versus 2.7 maanden voor de controlegroep (HR=0.49; p<0.0001)​​.
2. Ovariumkanker (metastases):
   • Trial: Prospective controlled cohort studies on long-term therapy of ovarian cancer patients with mistletoe (Viscum album L.) extracts iscador.
   • Resultaat: Hazard ratio voor overleving was significant in de OvarMetRand studie (HR=0.40; 95% CI: 0.15, 1.03)​​.
3. Corpus Uteri Kanker:
   • Trial: Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador).
   • Resultaat: Significante verbetering van overleving in de eerste gerandomiseerde studie (HR=0.36; 95% CI: 0.16, 0.82)​​.
4. Niet-gemetastaseerd Mammacarcinoom:
   • Trial: Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma.
   • Resultaat: Significant langere overleving in de mistletoe extract groep (HR=0.46; 95% CI: 0.22, 0.96)​​.

Verbetering van Kwaliteit van Leven (Quality of Life)

1. Geavanceerde Pancreaskanker:
   • Trial: Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial.
   • Resultaat: Significant verbetering in kwaliteit van leven op alle 6 functionele schalen en 7 van de 9 symptoomschalen​​.
2. Borstkanker:
   • Trial: Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial.
   • Resultaat: Significant verbetering in fysieke, emotionele en functionele welzijnsschalen en totale QoL scores​​.
3. Maagkanker :
   • Trial: Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma – a randomized, controlled pilot study.
   • Resultaat: Significante verbetering in globale gezondheid status en verminderde frequentie van diarree​​.
4. Algemene Kanker (Borst-, Ovarium- en Niet-kleincellig longkanker):
   • Trial: Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial.
   • Resultaat: Significant verbetering van kwaliteit van leven volgens FLIC, TCM en KPI vragenlijsten​​.

Deze bevindingen suggereren dat mistelextracten mogelijk een positieve invloed kunnen hebben op kanker. De bewijskracht is echter zeer matig.